IFIH1 and dermatomyositis: Moreover, anti‐MDA5 DM mortality is significantly higher compared to other inflammatory myopathies with ILD such as anti‐synthetase syndrome, with a 5‐year mortality rate around 15% among anti‐Jo1 antibody positive [8] and approximately 25% for non‐Jo1 anti‐synthetase antibodies [9].